Insider Buying at KORU Medical Signals Confidence Amid Volatile Stock

Corporate Analysis: Insider Buying at KORU Medical Systems Signals Confidence in a Volatile Stock

Executive Summary

On May 18, 2026, Chief Technology Officer Eric Schiller purchased 5,000 shares of KORU Medical Systems at $3.91 per share, raising his ownership to a total of 5,000 shares. This transaction, occurring when the share price hovered near its 52‑week low of $2.63 and slightly above the closing price of $3.96, is part of a broader insider accumulation strategy that has been unfolding over the past five months. Schiller’s cumulative acquisitions—including option exercises and direct purchases—total more than 300,000 shares, reflecting a long‑term conviction in the company’s product pipeline and market positioning.

Insider Activity as a Market Indicator

Insider buying is traditionally interpreted as a signal of confidence, given that executives possess superior knowledge of upcoming developments such as regulatory approvals, product launches, and strategic partnerships. In KORU’s case, Schiller’s consistent, low‑price acquisitions—most recently buying 5,000 shares at $3.91—are indicative of a “buy‑low, hold‑long” strategy. The transaction size is modest relative to the overall shares outstanding, and the price is virtually identical to the market rate, suggesting that the trade is unlikely to provoke an immediate price surge. Nevertheless, the pattern of incremental purchases, coupled with a significant single trade by CEO Linda Tharby (1,191 shares at $3.92 on May 15), underscores a collective executive belief that the company’s valuation is poised for a rebound after a prolonged decline.

Historical Purchasing Patterns

Schiller’s equity transactions reveal a steady accumulation of shares through both option grants and direct purchases. In early January, he exercised 232,297 options and bought 76,426 shares, adding 308,723 shares to his portfolio. He has continued to buy shares on a quarterly basis, often at prices slightly below market, reflecting a patient‑capital approach that prioritizes company growth over short‑term portfolio adjustments. Notably, Schiller has not disclosed any significant divestitures, indicating a focus on long‑term value creation rather than liquidity needs.

Financial and Operational Context

KORU’s recent financials show a negative price‑earnings ratio of –76.2 and a 47 % yearly gain, suggesting that the stock is still undervalued relative to its earnings potential. The company’s focus on subcutaneous infusion devices for chronic conditions places it in a niche but expanding market; product approvals can create significant upside. Insider buying, especially from senior technical leadership, may signal expectations of forthcoming regulatory milestones or commercial traction that could justify a higher valuation. However, the market’s recent 6 % monthly decline and the high volatility implied by the 52‑week high of $6.61 indicate that any positive momentum will likely be gradual.

Market Trends, Reimbursement Strategies, and Technological Adoption

These trends reinforce KORU’s strategic positioning. By aligning its product development with value‑based reimbursement frameworks and leveraging connected device technology, the company can capture incremental market share while mitigating price pressure.

Implications for Investors

Executives’ buying activity provides a subtle yet meaningful barometer of internal confidence. While the trade itself is unlikely to move the stock dramatically, it complements a broader pattern of insider accumulation that may signal impending product or regulatory news. Analysts should monitor upcoming earnings releases and FDA submissions for KORU. A moderate buy or hold recommendation is appropriate for investors comfortable with the company’s valuation risk profile.

Transaction Log